BMY stock forecast, quote, news & analysis

Key Takeaways

• Bristol-Myers Squibb (BMY) traded near $61 in late October 2026, down roughly 2% over the trailing 30 days and holding within a relatively narrow trading range.
• The stock has gained approximately 14% year to date, supported by accelerating sales across newer medicines in its growth portfolio.
• Growth products such as Reblozyl, Breyanzi, Camzyos, Opdualag and Cobenfy now account for roughly 60% of total revenue, helping to offset erosion in legacy brands.
• Second-quarter 2026 results beat consensus estimates, and management raised its full-year revenue and earnings guidance.
• Declining sales for Revlimid and Pomalyst, plus the eventual loss of exclusivity on Eliquis, remain the primary long-term overhangs.
• A late-October safety disclosure in an early-stage CAR-T study for multiple sclerosis added near-term volatility to the share price.
• For additional context on valuation and results, explore BMY Price Targets, Earnings, and Forecast pages.
• Investors tracking automated strategies can also review Trending AI Robots for data-driven trading signals.

Current Market Snapshot

Bristol-Myers Squibb shares have moved in a contained range over the past month, closing near $61 in late October 2026 after trading between roughly $56 and $64 over the preceding several weeks. The roughly 2% pullback over the trailing 30 days stands in contrast to the stock's stronger year-to-date advance of about 14%, indicating that momentum has cooled as investors weigh pipeline execution against patent-related headwinds.

Analyst sentiment remains moderately positive, with a consensus "Moderate Buy" rating and an average price target near $66, though individual estimates vary widely. The stock also offers a dividend yield around 4%, which has historically attracted income-oriented investors during periods of price consolidation.

Bristol-Myers Squibb (BMY) Business Overview and Competitive Position

Bristol-Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and commercializing medicines across oncology, hematology, immunology, cardiovascular disease and neuroscience. Its best-known products include the blood thinner Eliquis, developed in collaboration with Pfizer, and the immuno-oncology therapy Opdivo.

The company is executing a portfolio transformation. While legacy blockbusters such as Revlimid and Pomalyst face generic competition, a newer "growth portfolio" spanning Reblozyl, Breyanzi, Camzyos, Opdualag, Sotyktu and the schizophrenia treatment Cobenfy is expanding rapidly and now represents close to 60% of total sales. This shift toward products with longer growth runways is central to the investment thesis, as it positions the company to offset declining legacy revenue while funding a pipeline that includes cell therapy and next-generation immunology assets.

Recent Developments Driving BMY

Second-quarter 2026 results, reported in late July, beat consensus expectations, with adjusted earnings per share of $2.04 on revenue of roughly $12.97 billion. Management raised full-year 2026 revenue guidance to approximately $49–$50 billion and non-GAAP EPS guidance to $6.75–$7.00, citing Eliquis strength and momentum across growth products.

Pipeline news has also influenced sentiment. In mid-October, the company reported positive Phase 3 results for admilparant in idiopathic pulmonary fibrosis and for RYZ101 in neuroendocrine tumors. However, a late-October disclosure of a patient death in an early-stage CAR-T study for multiple sclerosis triggered a decline of about 2% in the stock, underscoring the safety risks that accompany the cell therapy class.

On the strategic front, Bristol-Myers Squibb has deepened its use of artificial intelligence through collaborations with Pathos AI and Tempus AI, as well as partnerships with NVIDIA and Anthropic, aimed at improving drug discovery and trial design.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots drawn from a much larger universe of automated strategies. While Tickeron offers hundreds of bots trading thousands of tickers, only the top-performing and most relevant bots appear in this featured section. The bots differ in approach, timeframe and performance metrics, ranging from short-term swing strategies to longer-horizon models. For investors seeking a data-driven complement to fundamental research, exploring the section can offer a view into how automated systems are positioning across the market.

2026 Outlook and What Investors Should Watch

The next major catalyst is Bristol-Myers Squibb's third-quarter 2026 earnings report, expected in late October, which will test the durability of growth portfolio momentum and provide an update on full-year guidance. Beyond earnings, investors are watching pivotal clinical readouts, including the milvexian studies in stroke prevention and atrial fibrillation now expected in early 2027, as well as additional data on admilparant.

The gradual ramp of Cobenfy and the potential launches of the CELMoD candidates iberdomide and mezigdomide represent important long-term drivers. At the same time, the 2028 loss of exclusivity on Eliquis remains a key risk, alongside ongoing safety scrutiny of CAR-T therapies and broader regulatory and pricing pressures across the pharmaceutical sector. These factors will likely shape both the company's fundamentals and investor sentiment in the months ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations